Introduction

56
One third of the world population is estimated to have LTBI [1], a state of infection caused by
57
Mycobacterium tuberculosis (Mtb) characterized by temporary immune containment of the 58 bacteria and lack of any clinical or microbiologic evidence of active tuberculosis (TB). As these 59 subjects have no evidence of disease, they can currently be diagnosed only by measuring the 60 cutaneous Delayed Type Hypersensitivity reaction (tuberculin skin test, TST) or by measuring 61 production of Interferon-γ in the blood using interferon-γ release assays (IGRAs) [2] . It is 62 estimated that 5-10% of all subjects with LTBI will have a lifetime risk of progression to active 63 TB disease. Treatment of LTBI decreases the overall burden of active TB by 60-90% [3] . In low 64 burden TB countries like the US where the overall active TB rates are <10/1000 population, the Variables generated by the calculator 117 Using the above data, the calculator was used to generate a positive predictive value (PPV) for
118
TST performed to detect TB infection. As IGRAs have higher specificity for assessment of Mtb obtained from a large cohort of healthy TST-positive US military recruits followed up for 4 years 126 [9] . In this algorithm the highest annual risk is assigned (in descending order) to transplantation 127 requiring immunosuppressant therapy (7.4%), HIV (5%), pulmonary silicosis (3%), chronic renal 128 failure (requiring hemodialysis) (2.5%), carcinoma of the head and neck(1.6%), close contact of 129 person with active TB (1.5%) and recent TST/IGRA conversion (≤ 2years) (1.5% 
RESULTS
147
Characteristics of the study subjects 148 Table 1 shows the baseline demographic information for the study subjects. The median age was 149 49 years and a little less than half were female (43.31%). Of the 125 patients included, 94 were 150 from the US and US territories, 32 were non-US born and 1 subject had no documentation of 151 country of origin. Of the US-born individuals most were Caucasian (52%) or African American 152 (43%). The mean age at immigration for non-US born subjects was 29.22 years. TST data were 153 available on 69 and IGRA data on 91 subjects. Of all 35 TST positive subjects who also had
154
IGRA results available, 19 were IGRA positive, 13 were IGRA negative and 1 indeterminate .
155
The Only 2 subjects with positive IGRA had a negative TST result (Figure 1) 
Risk of Reactivation
174
The overall distribution of risk factors in the study patients comparing US born with immigrants 175 is shown in Figure 2 . Subjects with HIV, diabetes, history of smoking, taking a TNF-α inhibitor 176 and on transplant immunosuppression were more common in US born subjects compared to 177 immigrants. The calculator allowed us to divide subjects with LTBI into "Low (<10% risk),"
178
"Intermediate (10-<50% risk)," and "High (50-100% risk)" cumulative risk groups. for all patients who tested positive on TST but negative on IGRA, the median cumulative risk 187 was 19% suggesting that they were not in the high risk group. 
Hepatitis while on LTBI treatment
216
The calculated risk of INH induced hepatitis correlates with the age of the patient more than any 217 of the other risk factors. Of the five patients that developed elevated LFTs, all were above 38 218 years of age with three being above 65 years. Only one was on INH and four were on rifampin.
219
The calculator estimated a risk of hepatitis of 1.2% for two of these subjects, 5% for two and 220 2.3% for one subject. Each patient was concomitantly using at least one other potentially 221 hepatotoxic medication. 
Treatment completion
224
Of the 125 subjects included in the analysis, 8 were not offered any treatment and 3 refused. 59 225 of 114 (52%) subjects were started on treatment with INH, 24 (21%) on 3HP, 23 (20%) on Rifampin and 8 (7%) on Rifabutin. 69 (61%) subjects completed the recommended duration of 227 therapy during the study period and none developed active TB. The completion rates of those 228 treated for LTBI were the best for 3HP and worst for Rifabutin, 75% and 50% subjects 229 respectively ( Table 3) . Amongst the documented reasons for stopping treatment early ( Figure   230 3), loss to follow-up accounted for a majority of incomplete treatments (23 subjects to improve treatment adherence [16] [17] [18] . This approach also minimizes the loss to follow up 306 which was the major reason for incomplete treatment in our cohort.
307
In agreement with the published literature on adherence with 3HP based regimens, we found the 308 highest rates of treatment completion in subjects prescribed 3HP compared to those receiving 309 INH or Rifampin. Surprisingly, we saw low rates of treatment completion seen with Rifampin or 310 Rifabutin only regimens. Cytochrome P (CYP) 450 isoenzyme induction by Rifamycin based 311 regimens remains a concern in subjects with HIV on ARVs. This is especially important as more 312 than 85% of subjects with HIV/AIDS were prescribed INH and only 30% were able to complete 313 treatment in our study. Current US guidelines recommend use of 3HP only with efavirenz (EFV) 
319
Subjects on TNF-α blockers are another high risk group at risk for TB disease reactivation. The 320 majority of subjects with LTBI in our study were referred because of recent TST/IGRA 321 conversion (within ≤ 2years) which put them at an even higher risk of TB reactivation disease.
322
Rifamycin based regimens have recently been shown to be effective with minimal side effects in 323 this group of patients [19] . Although only 25% of patients on TNF-α blockers were prescribed 324 3HP, 70% were able to successfully complete LTBI therapy. This is likely due to close clinic 325 follow-up that these patients receive for their underlying autoimmune disease.
326
Two important limitations of our study are the retrospective nature of the study and that subjects 327 already receiving care for co-morbid conditions at different clinics were referred to our 328 Infectious Diseases clinic, making them more likely to seek healthcare. These subjects are 329 therefore more likely to have higher rates of LTBI treatment completion compared to the overall 330 population of subjects with LTBI. Furthermore, as patients were often referred from community 331 and other specialty clinics, ID clinic providers were often aware of medical comorbidities for e.g.
332
HIV/AIDS, Diabetes, renal failure on dialysis, and ongoing use of TNF-α blocker use at initial 333 clinic assessment. Therefore we could not properly assess the actual frequency with which these 334 risk factors would be assessed had the provider not been made aware beforehand. Nevertheless,
335
we used relatively strict criteria for inclusion of subjects with previously untreated LTBI in our 336 study and had follow up data on the majority of our study cohort. Our study suggests that 337 tstin3d.com could be used in future prospective studies for determining a numerical risk of TB 338 progression in patients with LTBI for improved provider awareness of those at high risk.
can be improved by "risk score targeted" treatment (i.e. selecting a 3HP based regimen for all 341 subjects at high cumulative risk). The utility of "risk score targeted" treatment as a strategy for • Fibronodular disease on chest X-ray +Recent TST conversion (≤ 2 years ago)+renal failure on dialysis
• Smoker
• Smoker+ Recent TST conversion (≤ 2 years ago)
• Recent TST conversion (≤ 2 years ago) 
